Taraxasterol inhibits cell proliferation and angiogenesis in ovarian cancer by targeting EphA2

Ovarian Cancer (OC) is a prevalent gynecological malignancy, underscoring the urgency to discover novel therapeutic approaches that enhance both clinical efficacy and safety. Taraxasterol (TA), an important component of dandelion, has been reported to exhibit inhibitory effects on the progression of various tumors. However, its specific role in OC is yet to be reported. In this present study, we observed that TA significantly inhibits the proliferation of OC cells, promotes apoptosis and reduces OC cell migration and angiogenesis. Mechanistically, TA targets the EPH receptor A2 (EphA2) receptor, thereby inhibiting OC progression. In conclusion, the ability of TA to suppress both cell proliferation and angiogenesis in OC through EphA2 targeting suggests its potential utility as a therapeutic agent for OC.

Taraxasterol (TA); Ovarian cancer (OC); Apoptosis; Angiogenesis; EPH receptor A2 (EphA2)

[1] Dong L, Wang H, Gao Y, Wang S, Wang W. Long non-coding RNA PVT1 promotes the proliferation, migration and EMT process of ovarian cancer cells by regulating CTGF. Oncology Letters. 2023; 25: 71.

[2] Pecorino B, Lagana AS, Chiantera V, Ferrara M, Di Stefano AB, Di Donna MC, et al. Progression free survival, overall survival, and relapse rate in endometrioid ovarian cancer and synchronous endometrial-ovarian endometrioid cancer (SEO-EC): results from a large retrospective analysis. Medicina. 2022; 58: 1706.

[3] Wempe SL, Gamarra-Luques CD, Telleria CM. Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells. Cancer Growth and Metastasis. 2013; 6: 1–13.

[4] Li C, Liu VWS, Chan DW, Yao KM, Ngan HYS. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. International Journal of Gynecologic Cancer. 2012; 22: 15–22.

[5] Burnell M, Gentry-Maharaj A, Glazer C, Karpinskyj C, Ryan A, Apostolidou S, et al. Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK collaborative trial of ovarian cancer screening. Ultrasound in Obstetrics & Gynecology. 2020; 56: 267–275.

[6] Li J, Yan W, Ren F, Sang H. Tectorigenin inhibits inflammation in keratinocytes by inhibition of NLRP3 inflammasome regulated by the TLR4/NF-kB pathway. Allergologia et Immunopathologia. 2023; 51: 82–89.

[7] Liu L, Huan L, Zhang Y, Wei W, Chen Z, Xu D, et al. Ubiquitin-specific protease 8 inhibits lipopolysaccharide-triggered pyroptosis of human bronchial epithelial cells by regulating PI3K/AKT and NF-kB pathways. Allergologia et Immunopathologia. 2022; 50: 96–103.

[8] Ghoneum A, Gonzalez D, Afify H, Shu J, Hegarty A, Adisa J, et al. Compound C inhibits ovarian cancer progression via PI3K-AKT-mTOR-NFkB pathway. Cancers. 2022; 14: 5099.

[9] Li M, He Y, Zhang W, Yin Y, Jiang Q, Loor JJ, et al. Taraxasterol alleviates fatty acid-induced lipid deposition in calf hepatocytes by decreasing ROS production and endoplasmic reticulum stress. Journal of Animal Science. 2023; 101: skad015.

[10] Sang R, Ge B, Li H, Zhou H, Yan K, Wang W, et al. Taraxasterol alleviates aflatoxin B1-induced liver damage in broiler chickens via regulation of oxidative stress, apoptosis and autophagy. Ecotoxicology and Environmental Safety. 2023; 251: 114546.

[11] Jiao F, Tan Z, Yu Z, Zhou B, Meng L, Shi X. The phytochemical and pharmacological profile of taraxasterol. Frontiers in Pharmacology. 2022; 13: 927365.

[12] Ge B, Sang R, Wang W, Yan K, Yu Y, Kong L, et al. Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in vitro and in vivo experiments. Phytomedicine. 2023; 116: 154872.

[13] Li Z, Lian Y, Wei R, Jin L, Cao H, Zhao T, et al. Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kB and Nrf2/HO-1 signaling pathways. Life Sciences. 2020; 262: 118546.

[14] Zhao Y, Zhang L, Guo M, Yang H. Taraxasterol suppresses cell proliferation and boosts cell apoptosis via inhibiting GPD2-mediated glycolysis in gastric cancer. Cytotechnology. 2021; 73: 815–825.

[15] Zhu J, Li X, Zhang S, Liu J, Yao X, Zhao Q, et al. Taraxasterol inhibits TGF-b1-induced epithelial-to-mesenchymal transition in papillary thyroid cancer cells through regulating the Wnt/b-catenin signaling. Human & Experimental Toxicology. 2021; 40: S87–S95.

[16] Tang CT, Yang J, Liu ZD, Chen Y, Zeng C. Taraxasterol acetate targets RNF31 to inhibit RNF31/p53 axis-driven cell proliferation in colorectal cancer. Cell Death Discovery. 2021; 7: 66.

[17] Bao T, Ke Y, Wang Y, Wang W, Li Y, Wang Y, et al. Taraxasterol suppresses the growth of human liver cancer by upregulating Hint1 expression. Journal of Molecular Medicine. 2018; 96: 661–672.

[18] Sun Q, Suo Y, Lv H, Wang Q, Yin H. Porphin e6 complex loaded with gold nanorod mesoporous silica enhances photodynamic therapy in ovarian cancer cells in vitro. Lasers in Medical Science. 2023; 38: 115.

[19] Zhang X, Xiong H, Liu L. Effects of taraxasterol on inflammatory responses in lipopolysaccharide-induced RAW 264.7 macrophages. Journal of Ethnopharmacology. 2012; 141: 206–211.

[20] Sang R, Yu Y, Ge B, Xu L, Wang Z, Zhang X. Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-kB and Bax/Bc1-2 signalling pathways. Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47: 3929–3937.

[21] Alhasan L, Addai Z. Allicin-induced modulation of angiogenesis in lung cancer cells (A549). Tropical Journal of Pharmaceutical Research. 2018; 17: 2129–2134.

[22] Luan Y, Luan Y, Feng Q, Chen X, Ren K, Yang Y. Emerging role of mitophagy in the heart: therapeutic potentials to modulate mitophagy in cardiac diseases. Oxidative Medicine and Cellular Longevity. 2021; 2021: 3259963.

[23] Wang Y, Gong J, Ding X, Luo S. CircRTTN upregulates EPHA2 to aggravate the malignant process of melanoma via sponging miR-890. Histology & Histopathology. 2024; 39: 211–224.

[24] Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007; 109: 332–340.

[25] Lu C, Shahzad MMK, Wang H, Landen CN, Kim SW, Allen J, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biology & Therapy. 2008; 7: 1098–1103.